Cornelia Braicu has received a research grant financed by THE NATIONAL PLAN FOR RESEARCH, DEVELOPMENT AND INNOVATION 2007–2013 (PNII) with the title: “Modulation of pro/anticarcinogenic effect of toxic chemical agents in breast cancer multitargeted therapy (CANCERTER-p53). This evidence concerns the gene TP53 and breast cancer.